Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland

OBJECTIVES: To assess cost implications per patient, per year, and to predict the potential annual budget impact when patients with bone metastases secondary to solid tumours at risk of skeletal-related events (SREs) transition from zoledronic acid (ZA; 4 mg every 3–4 weeks) to denosumab (120 mg eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lothgren, Mickael, Ribnicsek, Erna, Schmidt, Louise, Habacher, Wolfgang, Lundkvist, Jonas, Pfeil, Alena M, Biteeva, Irina, Vrouchou, Polina, Bracco, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717600/
https://www.ncbi.nlm.nih.gov/pubmed/23888248
http://dx.doi.org/10.1136/ejhpharm-2012-000235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717600/
https://www.ncbi.nlm.nih.gov/pubmed/23888248
http://dx.doi.org/10.1136/ejhpharm-2012-000235

Ejemplares similares